Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
Trial record 1 of 1 for:    Amyvid A18
Previous Study | Return to List | Next Study

Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline

This study has been completed.
Sponsor:
Collaborator:
Eli Lilly and Company
Information provided by (Responsible Party):
Avid Radiopharmaceuticals
ClinicalTrials.gov Identifier:
NCT01703702
First received: October 5, 2012
Last updated: July 8, 2016
Last verified: July 2016

October 5, 2012
July 8, 2016
October 2012
April 2015   (final data collection date for primary outcome measure)
  • Clinical and Diagnostic Change in Patient Management [ Time Frame: Baseline and 3 months ] [ Designated as safety issue: No ]
    Comparison of the percentage of patients who have a change in management from baseline to 3 months for patients who receive scan results immediately (intervention arm) and those who receive scan results 12 months later (control arm).
  • Change in ADAS-Cog 11 Total Score [ Time Frame: Baseline and 12 months ] [ Designated as safety issue: No ]
    Change from baseline in the Alzheimer's Disease Assessment Scale - cognitive subscale (ADAS-cog) 11 Score in patients with mild impairment by positive or negative florbetapir (18F) PET scan result (Aß+/Aß-). ADAS-Cog scores (range 0-70) indicate performance on a series of 11 cognitive tasks where 0 indicates the highest level of cognitive performance and 70 indicates the lowest level of cognitive performance. Change in ADAS-Cog scores were calculated by subtracting the baseline score from the 12 month score. A change in ADAS-Cog greater than 0 indicates a deterioration in cognitive performance whereas a change in ADAS-Cog less than 0 indicates improved cognitive performance.
  • Patient Management [ Time Frame: baseline, 3 months and 12 months ] [ Designated as safety issue: No ]
    Comparison of the proportion of patients who have a change in management from baseline to 3 months for patients who receive scan results immediately (intervention arm) and those who receive scan results 12 months later (control arm).
  • Patient Prognosis [ Time Frame: baseline and 12 months ] [ Designated as safety issue: No ]
    Association between scan status and cognitive decline.
Complete list of historical versions of study NCT01703702 on ClinicalTrials.gov Archive Site
  • Change in Patient's Clinical Diagnosis [ Time Frame: Baseline and 3 months ] [ Designated as safety issue: No ]
    Comparison of the percentage of patients who have a change in diagnosis from baseline to 3 months for patients in the intervention and control arms for whom the scan result was not predicted by the initial diagnosis.
  • Change in Diagnostic Confidence [ Time Frame: Baseline and 3 months ] [ Designated as safety issue: No ]
    Comparison of the percentage point change in the physician's diagnostic confidence from baseline to month 3 in the intervention and control arms for patients whose scan result was predicted by their baseline clinical diagnosis. Diagnostic confidence was recorded by the physician as a whole number percent from 0-100% and the change in confidence was calculated by subtracting the baseline confidence from the confidence recorded at the specified timepoint. Values greater than zero reflect increased diagnostic confidence; values less than zero reflect decreased diagnostic confidence.
  • Change in Patient Management: Advice/Counseling [ Time Frame: Baseline and 3 months ] [ Designated as safety issue: No ]
    Comparison of the percentage of patients in the intervention and control arms who have a change in management relating to advice and counseling from baseline to 3 months.
  • Change in Caregiver Self-efficacy [ Time Frame: Baseline and 3 months ] [ Designated as safety issue: No ]
    Comparison of the change in self-efficacy between intervention and control arms. Change in self-efficacy is defined as the difference between total score on the Fortinsky: Family caregivers' self-efficacy for managing dementia scale at Follow-up (3 months) and baseline. Self-efficacy for managing dementia is defined in terms of specific behaviors or tasks that can be learned, and that are highly relevant to daily management of the disease process. The scale consists of 10 questions, each with responses ranging from 1 (not at all certain) to 10 (very certain). The total score is calculated by summing the response for each item. The total score ranges from 10 to 100, with increasing scores representing increasing caregiver self-efficacy.
  • Change in Patient Management: Individual Categories [ Time Frame: Baseline and 3 months ] [ Designated as safety issue: No ]
    Compare the percentage of patients with a change from baseline in the individual patient management categories at 3 months in the interventional and control arms.The individual categories are: Major diagnostic tests, Alzheimer's/cognition medication, neuropsychological tests, physician follow-up for re-evaluation or specialist referral.
  • Change in clinical diagnosis in patients for whom the scan results was not predicted by the initial diagnosis. [ Time Frame: Baseline and 3 months ] [ Designated as safety issue: No ]
    This objective will be to determine whether, at the 3 month time point, the scan information leads to (in the interventional arm compared to the control arm) a change in the clinical diagnosis in patients for whom the scan result was not predicted by the initial diagnosis. This measurement will compare the proportion of patients with scan results that were not predicted by the initial diagnosis and have a change in clinical diagnosis between the intervention and control arms
  • Change in treating physician's confidence in clinical diagnosis. [ Time Frame: Baseline and 3 months ] [ Designated as safety issue: No ]
    This objective will be to determine whether, at the 3 month time point, the scan information leads to (in the interventional arm compared to the control arm) a difference in the treating physician's confidence in clinical diagnosis. This will be measured by comparing the pre-scan confidence to the post-scan confidence among those patients with a scan result predicted by their baseline clinical diagnosis.
  • Change in patient and caregiver advice and counseling [ Time Frame: Baseline and 3 months ] [ Designated as safety issue: No ]
    This objective will be to determine whether, at the 3 month time point, the scan information leads to (in the interventional arm compared to the control arm) a difference in the percentage of patients who have a change in management relating to patient and caregiver advice and counseling.
  • Caregiver self-efficacy for managing dementia score. [ Time Frame: Baseline and 3 months ] [ Designated as safety issue: No ]
    This objective will be to determine whether, at the 3 month time point, the scan information leads to (in the interventional arm compared to the control arm) a difference in caregiver self-efficacy for managing dementia score (on the Fortinsky scale), adjusted for baseline self-efficacy.
Not Provided
Not Provided
 
Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline
A Randomized, Multicenter, Multicountry Study to Evaluate the Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and to Evaluate the Relationship Between Florbetapir (18F) PET Scan Status and Cognitive Decline
This study is designed to determine the effectiveness of florbetapir (18F) in changing patient management and to evaluate the association between scan status and cognitive decline.
Not Provided
Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Alzheimer's Disease
Drug: florbetapir (18F)
Single i.v. bolus injection of 370MBq (10 mCi) followed by saline flush, 50 minutes prior to imaging, 10 minute image duration
Other Names:
  • 18F-AV-45
  • florbetapir F 18
  • AV-45
  • Amyvid
  • Experimental: Intervention
    Subjects will receive florbetapir (18F) PET scans and physicians will have immediate access to PET scan results.
    Intervention: Drug: florbetapir (18F)
  • Experimental: Control
    Subjects will receive florbetapir (18F) PET scans but physicians will be blinded to PET scan results for 12 months
    Intervention: Drug: florbetapir (18F)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
641
April 2015
April 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

Patients may be enrolled in the mild impairment (not demented) group if the following criteria are met:

  1. Males or females ≥ 50 to <= 90 years of age.
  2. Have cognitive decline verified by a study partner or cognitive impairment verified by the study physician.
  3. Have a study partner who provides separate consent and is willing to accompany the patient on all of the study visits.
  4. Have an MMSE score of 24 to 30 inclusive.
  5. Can tolerate a 10-minute PET scan.
  6. Have the ability to cooperate and comply with all study procedures.
  7. Have an enrolling physician who has less than high confidence in their diagnosis for the patient related to the cognitive decline at the time of enrollment.
  8. Ability to provide informed consent for study procedures.

Patients may be enrolled in the dementia group if the following criteria are met:

  1. Are males or females ≥ 50 to <= 90 years of age.
  2. Meet clinical criteria for dementia.
  3. Have a caregiver who provides separate consent and is willing to accompany the patient on all of the study visits.
  4. Have an MMSE score of 16 to 24 inclusive.
  5. Have not received a clinical examination and/or laboratory test results that strongly indicates a non-neurodegenerative cause for the patients cognitive impairment.
  6. Can tolerate a 10-minute PET scan.
  7. Have the ability to cooperate and comply with all study procedures.
  8. Have an enrolling physician who has less than high confidence in their diagnosis for the patient related to the cognitive decline at the time of enrollment.
  9. Ability to provide informed consent for study procedures. (If the patient is incapable of giving informed consent, the patient's legal representative may consent on behalf of the patient but the patient must still confirm assent. This person may serve as the study partner as well).

Exclusion Criteria:

Patients will be excluded from enrollment if they:

  1. Have a current serious or unstable illness;
  2. The patient or enrolling physician knows the result of a previous amyloid imaging scan;
  3. The patient has a known brain lesion, pathology or alternative diagnosis that strongly explains the patient's clinical presentation;
  4. Are receiving any investigational medications, or have participated in a trial with investigational medications within the last 30 days;
  5. Have ever participated in an experimental study with an amyloid targeting agent (e.g. anti-amyloid immunotherapy, γ -secretase or β -secretase inhibitor) unless it can be documented that the patient received only placebo during the course of the trial;
  6. Have had a radiopharmaceutical imaging or treatment procedure within 7 days prior to the study imaging session; or
  7. Are females of childbearing potential who are not surgically sterile, not refraining from sexual activity or not using reliable methods of contraception.

Patients will also be excluded from enrollment if their enrolling physician:

  1. Does not consider Alzheimer's disease as a potential cause of the patient's cognitive decline.
  2. Is not the primary physician taking care of the patient with respect to the management of their cognitive impairment.
  3. Cannot categorize the patient as either: a) having a documented and completed evaluation for cognitive decline within the past 18 months old; or b) currently undergoing evaluation for cognitive decline.
  4. Is unwilling to suspend all testing and other evaluation procedures between the time of the baseline evaluation of the enrolling physician's diagnosis and management plan and the time the completion of the PET scan.
Both
50 Years to 90 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States,   France,   Italy
 
NCT01703702
18F-AV-45-A18
No
Not Provided
Not Provided
Avid Radiopharmaceuticals
Avid Radiopharmaceuticals
Eli Lilly and Company
Study Director: Chief Medical Officer Avid Radiopharmaceuticals
Avid Radiopharmaceuticals
July 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP